desktop-banner
joseph-image

Not an actual patient.

Meet Joseph

Age: 76

Medical history: Hypothyroidism (controlled), high cholesterol, hypertension, arthritis, type 2 diabetes mellitus, mCSPC → mCRPC

Current labs/imaging:

BRCA2 positive

  • Gleason score 9 (5+4)
  • PSA 28 ng/mL
  • ECOG PS 1
  • 5 sites of metastases (lung and 4 bone lesions–one outside of the spine/pelvis identified by PSMA PET)

Treatment for mCSPC: ARI + ADT

Current medications: 8

Recently, Joseph underwent germline and somatic testing and was diagnosed with BRCAm mCRPC. What’s next for Joseph in his treatment journey?

Treatment journey1

A treatment progression diagram for metastatic prostate cancer, showing transitions from mCSPC to mCRPC with specific therapies, and ending with the question of what's next for his BRCAm mCRPC.A treatment progression diagram for metastatic prostate cancer, showing transitions from mCSPC to mCRPC with specific therapies, and ending with the question of what's next for his BRCAm mCRPC.

Note: Joseph tested positive for BRCAm while on abiraterone acetate + GnRH + prednisone, a 1L mCRPC treatment he has taken for 2 months.

Concomitant medications for other medical conditions

  • Levothyroxine for hypothyroidism

    • 1 tablet once daily on an empty stomach

  • Rosuvastatin for high cholesterol

    • 1 tablet once daily

  • Losartan for hypertension

    • 1 tablet once daily

  • Dapagliflozin for type 2 diabetes mellitus

    • 1 tablet once daily

  • Diclofenac for arthritis

    • 1 tablet twice daily

Joseph is worried a new therapy will add to the burden of managing his current medications and co-pays.

How AKEEGA® may help patients like Joseph

47%

reduced risk of disease
progression or death vs
placebo + AAP2*
HR, 0.53 (95% CI, 0.36-0.79); P=0.0014

Efficacy
pills icon

Once-daily
dual action tablets
under 1 co-pay†

Dosing
85%

of patients with BRCAm
mCRPC remained on AKEEGA®
without discontinuing due
to ARs2

Safety

*MAGNITUDE is a phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating treatment with AKEEGA® with prednisone vs standard of care (AAP). Cohort 1 consists of 423 subjects with mCRPC and HRR mutations, of which 225 subjects have BRCA mutations, who were randomized (1:1) to receive either AKEEGA® (n=212) or placebo and abiraterone acetate (n=211) once daily until unacceptable toxicity or progression. All patients received prednisone 10 mg daily and either received a GnRH analog or had prior bilateral orchiectomy. AKEEGA® significantly reduced the risk of disease progression or death by 47% [HR, 0.53 (95% CI, 0.36-0.79) P=0.0014] in patients with BRCAm mCRPC.2,3

†AKEEGA® offers simplified dosing in a dual action tablet that combines PARPi and NHT. The recommended AKEEGA® dose is 200 mg niraparib/1,000 mg abiraterone acetate (2 tablets, once daily). AKEEGA® is indicated with 10 mg prednisone daily.2

1L, first line; AAP, abiraterone acetate (AA) + prednisone (P); ADT, androgen deprivation therapy; ARI, androgen receptor inhibitor; AR, adverse reaction; BRCAm, BRCA gene-mutated; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GnRH, gonadotropin-releasing hormone; HR, hazard ratio; HRR, homologous recombination repair; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; NHT, novel hormonal therapy; PARPi, poly (ADP-ribose) polymerase inhibitor; PS, performance status; PSA, prostate-specific antigen; PET, positron emission tomography; PSMA, prostate-specific membrane antigen.

References:

  1. Data on file. Janssen Biotech, Inc.
  2. AKEEGA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  3. Chi KN, Rathkopf D, Smith MR, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(18):3339-3351. doi:10.1200/JCO.22.01649